Pacific Biosciences of California (PACB)

History and Background

Pacific Biosciences of California (PacBio) was founded in 2004. It is known for its Single Molecule, Real-Time (SMRT) sequencing technology, offering long-read sequencing solutions. Key milestones include the commercial launch of its first sequencer in 2011 and continuous advancements in accuracy and throughput.

Core Business Areas

• Sequencing Systems: Develops and manufactures DNA sequencing systems utilizing SMRT technology, designed for long-read sequencing applications. Products are used by researchers in various fields including genomics, transcriptomics, and epigenetics.
• Consumables: Supplies consumables required for operating PacBio sequencing systems, including SMRT Cells and reagents.
• Services: Offers services related to sequencing projects, including sequencing, data analysis, and consultation services.

Leadership and Structure

Christian Henry is the President and CEO. The company has a typical corporate structure with departments focusing on R&D, Sales & Marketing, Operations, and Finance.

Key Offerings

• Revio: Revio is PacBio's latest long-read sequencing system, offering high throughput and improved cost-effectiveness. Competitors include Illumina and Oxford Nanopore. PacBio states the Revio system can deliver up to 1,300 human genomes per year at a list price of $779,000 USD per system. Market share information specific to Revio is not publicly available. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies (private).
• Sequel II/IIe Systems: These platforms offer accurate long-read sequencing and are widely used for de novo genome assembly, structural variant detection, and isoform sequencing. Competitors include Illumina and Oxford Nanopore. No specific market share is known. Competitors include Illumina (ILMN) and Oxford Nanopore Technologies (private).
• Consumables (SMRT Cells, Reagents): Required for running PacBio sequencing systems; revenue dependent on instrument usage. No specific data available on revenue for this product. Competitors are those that provide reagents for competing sequencing platforms.

Industry Overview

The genomics and sequencing market is rapidly growing, driven by advancements in technology, decreasing sequencing costs, and increasing applications in healthcare, research, and agriculture.

Positioning

PacBio specializes in long-read sequencing, offering advantages in resolving complex genomic regions and identifying structural variations compared to short-read technologies. It positions itself as a leader in high-accuracy long-read sequencing.

Total Addressable Market (TAM)

The global genomics market is expected to reach hundreds of billions of dollars. PacBio is well-positioned to capture a significant share of the long-read sequencing segment.

Key Competitors

• ILMN
• ONT.L

Competitive Landscape

PacBio excels in long-read accuracy but faces challenges from Illumina's dominance in the overall sequencing market. Oxford Nanopore provides another alternative long-read solution.

Historical Growth: PacBio has experienced revenue growth driven by increased adoption of its sequencing platforms and consumables.

Future Projections: Analyst estimates project continued revenue growth driven by the Revio system and expanding applications of long-read sequencing.

Recent Initiatives: The launch of the Revio system, strategic partnerships, and expansion into new market segments.

PacBio is a leading player in long-read sequencing with advanced technology and a growing market. While it faces competition from industry giants, the increasing demand for long-read data and continuous innovation position it for future growth. However, cost and throughput limitations are areas where the company needs to improve to gain more market share. The company also needs to watch out for disruptive technologies entering the market.

Data Sources:

• Company filings
• Analyst reports
• Industry publications

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Market share and financial data is estimated and subject to change.